V1RE9 Inhibitors
V1RE9 inhibitors belong to a class of chemical compounds designed to interact with and inhibit the function of a specific molecular target identified as V1RE9, which is a part of a biochemical pathway within organisms. The exact nature of V1RE9 has not been disclosed in this description, but inhibitors of such entities typically function by binding to the target molecule and obstructing its normal activity. The design of V1RE9 inhibitors is a sophisticated process that often involves a deep understanding of the molecular structure of V1RE9 itself. Through techniques such as X-ray crystallography or NMR spectroscopy, scientists are able to discern the three-dimensional configuration of the target, which allows for the rational design of molecules that can interact with the target site specifically and with high affinity.
The development and synthesis of V1RE9 inhibitors require meticulous optimization of the inhibitor molecules to ensure that they have the desired properties, such as the ability to bind to the V1RE9 with sufficient strength and specificity, while also having suitable chemical stability and appropriate physicochemical characteristics to interact with the biological environment where V1RE9 is located. The process often involves iterative cycles of design, synthesis, and testing to refine the inhibitor molecules. Inhibitors may vary widely in their chemical structure, with some being small organic molecules, while others might be larger and more complex entities such as peptides or even antibody-like molecules. The structural diversity of V1RE9 inhibitors is reflective of the versatility of modern chemical science in addressing complex molecular recognition challenges. While the specific interactions between V1RE9 inhibitors and their target are determined by the precise shape and electronic properties of the binding site on V1RE9, common interactions include hydrogen bonds, hydrophobic interactions, and sometimes covalent bonding, each contributing to the overall inhibitory effect.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
A selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. FGFR signaling is critical for the activation of several pathways including the PI3K/AKT pathway, which can indirectly regulate V1RE9 function by modulating downstream effector molecules that might interact with V1RE9. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphatidylinositol 3-kinase (PI3K). Since PI3K is involved in the activation of AKT, inhibition of PI3K leads to reduced AKT activity, which in turn could downregulate pathways relevant to V1RE9 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of ROCK (Rho-associated protein kinase), which is implicated in actin cytoskeleton organization. Disruption of actin dynamics can lead to altered cell signaling, potentially affecting V1RE9-associated pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress- and cytokine-induced signaling pathways. By inhibiting JNK, SP600125 could interfere with transcriptional events that regulate V1RE9 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAP kinase which is involved in response to stress and inflammation. Inhibition of p38 MAPK could alter cellular responses that normally involve V1RE9. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, U0126 can suppress ERK activation, potentially affecting V1RE9-related signaling processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can suppress the mTORC1 pathway, which is crucial for cell growth and metabolism. As such, rapamycin could indirectly affect V1RE9 by altering the cellular environment it operates within. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that acts in a similar fashion to LY294002, leading to reduced AKT activity and affecting downstream pathways that may regulate V1RE9. | ||||||
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $308.00 | 5 | |
A potent and selective inhibitor of the Gs alpha subunit of G-proteins. Given that G-protein-coupled signaling can impact numerous cellular pathways, NF449 could indirectly affect V1RE9 function by altering G-protein signaling dynamics. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A selective inhibitor of Src family tyrosine kinases. Src kinases are involved in multiple signaling pathways that could govern cellular processes impacting V1RE9 activity. | ||||||